EFR3B

Chr 2

EFR3 homolog B

Also known as: KIAA0953

The EFR3B protein is a component of a complex that localizes phosphatidylinositol 4-kinase to the plasma membrane and regulates phosphatidylinositol 4-phosphate synthesis, serving as the membrane-anchoring component of this complex. Mutations in EFR3B cause autosomal recessive developmental and epileptic encephalopathy with onset in infancy or early childhood. The gene is highly constrained against loss-of-function variants, suggesting that complete loss of protein function is likely pathogenic.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
3
Pubs (1 yr)
19
P/LP submissions
0%
P/LP missense
0.44
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryEFR3B
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.27) despite low pLI — interpret in context.
📋
ClinVar Variants
19 unique Pathogenic / Likely Pathogenic· 83 VUS of 111 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Missense constrained — critical functional residues
LoF Constraint
0.44LOEUF
pLI 0.024
Z-score 4.52
OE 0.27 (0.170.44)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
4.26Z-score
OE missense 0.46 (0.410.51)
228 obs / 494.8 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.27 (0.170.44)
00.351.4
Missense OE0.46 (0.410.51)
00.61.4
Synonymous OE0.68
01.21.6
LoF obs/exp: 12 / 44.6Missense obs/exp: 228 / 494.8Syn Z: 3.56
DN
0.6357th %ile
GOF
0.6442th %ile
LOF
0.4038th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

111 submitted variants in ClinVar

Classification Summary

Pathogenic18
Likely Pathogenic1
VUS83
Benign1
18
Pathogenic
1
Likely Pathogenic
83
VUS
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
18
0
18
Likely Pathogenic
0
0
1
0
1
VUS
0
71
12
0
83
Likely Benign
0
0
0
0
0
Benign
0
0
1
0
1
Total071320103

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

EFR3B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC